These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9373659

  • 21. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG, Silva DL, Nunan FA, Nunan EA, Fernandes AP, Ferreira LA.
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [Abstract] [Full Text] [Related]

  • 22. Cutaneous leishmaniasis treatment.
    Minodier P, Parola P.
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [Abstract] [Full Text] [Related]

  • 23. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
    Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N, Boukthir A, Chlif S, Abdelhamid K, El Ahmadi Z, Louzir H, Mokni M, Morizot G, Buffet P, Smith PL, Kopydlowski KM, Kreishman-Deitrick M, Smith KS, Nielsen CJ, Ullman DR, Norwood JA, Thorne GD, McCarthy WF, Adams RC, Rice RM, Tang D, Berman J, Ransom J, Magill AJ, Grogl M.
    N Engl J Med; 2013 Feb 07; 368(6):524-32. PubMed ID: 23388004
    [Abstract] [Full Text] [Related]

  • 24. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador.
    Krause G, Kroeger A.
    Trans R Soc Trop Med Hyg; 1994 Feb 07; 88(1):92-4. PubMed ID: 8154018
    [Abstract] [Full Text] [Related]

  • 25. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole.
    Chacko A, Joseph M, Feltis T, Morris SK.
    Am J Trop Med Hyg; 2016 Oct 05; 95(4):793-794. PubMed ID: 27549634
    [Abstract] [Full Text] [Related]

  • 26. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis.
    Neal RA, Murphy AG, Olliaro P, Croft SL.
    Trans R Soc Trop Med Hyg; 1994 Oct 05; 88(2):223-5. PubMed ID: 8036682
    [Abstract] [Full Text] [Related]

  • 27. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
    Flaig MJ, Rupec J, Ruzicka T, Rupec RA.
    Hautarzt; 2007 Aug 05; 58(8):689-90, 692. PubMed ID: 17676349
    [Abstract] [Full Text] [Related]

  • 28. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.
    Varikuti S, Oghumu S, Saljoughian N, Pioso MS, Sedmak BE, Khamesipour A, Satoskar AR.
    Acta Trop; 2017 Sep 05; 173():102-108. PubMed ID: 28602835
    [Abstract] [Full Text] [Related]

  • 29. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
    Bavarsad N, Fazly Bazzaz BS, Khamesipour A, Jaafari MR.
    Acta Trop; 2012 Oct 05; 124(1):33-41. PubMed ID: 22750480
    [Abstract] [Full Text] [Related]

  • 30. Occlusive paromomycin for cutaneous leishmaniasis.
    Bryceson AD.
    Lancet; 1997 May 17; 349(9063):1477. PubMed ID: 9164342
    [No Abstract] [Full Text] [Related]

  • 31. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.
    Sosa N, Capitán Z, Nieto J, Nieto M, Calzada J, Paz H, Spadafora C, Kreishman-Deitrick M, Kopydlowski K, Ullman D, McCarthy WF, Ransom J, Berman J, Scott C, Grogl M.
    Am J Trop Med Hyg; 2013 Sep 17; 89(3):557-563. PubMed ID: 23857024
    [Abstract] [Full Text] [Related]

  • 32. Treatment of New World cutaneous and mucosal leishmaniases.
    Berman JD.
    Clin Dermatol; 1996 Sep 17; 14(5):519-22. PubMed ID: 8889330
    [Abstract] [Full Text] [Related]

  • 33. [Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].
    Santos AM, Noronha EF, Ferreira LA, Carranza-Tamayo CO, Cupolillo E, Romero GA.
    Rev Soc Bras Med Trop; 2008 Sep 17; 41(5):444-8. PubMed ID: 19009183
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
    Schmidt-Ott R, Klenner T, Overath P, Aebischer T.
    Trans R Soc Trop Med Hyg; 1999 Sep 17; 93(1):85-90. PubMed ID: 10492799
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial.
    Asilian A, Davami M.
    Clin Exp Dermatol; 2006 Sep 17; 31(5):634-7. PubMed ID: 16780497
    [Abstract] [Full Text] [Related]

  • 39. Occlusive paromomycin for cutaneous leishmaniasis.
    Bell SA, Schaller M, Röcken M.
    Lancet; 1997 Jan 04; 349(9044):29. PubMed ID: 8988124
    [No Abstract] [Full Text] [Related]

  • 40. Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America.
    Sandoval Pacheco CM, Araujo Flores GV, Favero Ferreira A, Sosa Ochoa W, Ribeiro da Matta VL, Zúniga Valeriano C, Pereira Corbett CE, Dalastra Laurenti M.
    Int J Exp Pathol; 2018 Oct 04; 99(5):249-257. PubMed ID: 30478864
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.